Qlosi

Drug Overview

Presbyopia is a natural, age-related condition that eventually affects nearly everyone, typically beginning around the age of 40. It manifests as a gradual loss of the eye’s ability to focus on nearby objects, leading to the common frustration of needing reading glasses or “longer arms.” Within the Ophthalmology category, a significant advancement in pharmacological treatment has emerged with the introduction of Qlosi. Operating as a Miotic and a Cholinergic Agonist, this medication offers a non-invasive alternative to traditional corrective lenses for individuals seeking to restore their near vision.

Qlosi represents a targeted therapy designed to utilize the eye’s natural physiology to overcome the stiffening of the crystalline lens. Unlike traditional treatments that rely on physical magnification, this drug modifies the optical properties of the eye through chemical signaling. It is specifically formulated to be a preservative-free solution, which is a critical feature for maintaining long-term ocular surface health in aging patients who may already be prone to dryness.

• Generic Name: Pilocarpine hydrochloride ophthalmic solution 0.4%
• US Brand Names: Qlosi
• Route of Administration: Topical Drops (Ophthalmic Solution)
• FDA Approval Status: Fully FDA-approved for the treatment of presbyopia in adults.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Qlosi works, one must first understand the “pinhole effect.” In a camera, a smaller aperture increases the depth of field, making objects at various distances appear sharp simultaneously. Qlosi achieves this within the human eye by acting as a cholinergic muscarinic agonist.

At the molecular level, the active ingredient, pilocarpine, binds to muscarinic receptors (specifically the M³ subtype) located on the iris sphincter muscle. This binding triggers a biological signal that causes the muscle to contract, a process known as miosis. The resulting constriction of the pupil creates a smaller aperture through which light enters the eye. By narrowing the pupil, the “pinhole effect” is induced, which naturally increases the depth of focus. This allows the patient to see near objects—such as text on a smartphone or a restaurant menu—more clearly without significantly blurring their distance vision.

Furthermore, pilocarpine acts on the muscarinic receptors of the ciliary muscle. When the ciliary muscle contracts, it can lead to a slight increase in the accommodative power of the lens. However, at the specific 0.4% concentration found in Qlosi, the primary mechanism driving visual improvement is the pupillary miosis. This lower concentration is a strategic choice designed to maximize the “pinhole” benefits while minimizing the side effects often associated with higher concentrations of cholinergic agents, such as “brow ache” or excessive near-focusing (myopic shift).

FDA-Approved Clinical Indications

The primary application of Qlosi is focused on the functional restoration of near visual acuity in the aging population.

• Primary Indication: Qlosi is indicated for the treatment of presbyopia in adults. This is its specific use for improving near vision that has declined due to age-related changes in the eye’s lens.
• Other Approved & Off-Label Uses:
  • Glaucoma (Off-label at this concentration): While higher concentrations of pilocarpine (1% to 4%) are FDA-approved for reducing intraocular pressure (IOP) in glaucoma, the 0.4% concentration in Qlosi is generally used for presbyopia.
  • Reversal of Mydriasis (Off-label): Used occasionally to constrict the pupil after it has been dilated for a clinical eye exam.
  • Adie’s Tonic Pupil (Diagnostic): Low-dose pilocarpine is sometimes used as a diagnostic tool to evaluate pupillary abnormalities.

Primary Ophthalmology Indications:

• Preserving Visual Acuity: By improving near vision, Qlosi helps preserve a patient’s functional visual acuity for daily tasks, reducing the dependency on multi-focal lenses or reading glasses.
• Stabilizing the Blood-Retinal Barrier: While not its primary role, the controlled use of cholinergic agents helps maintain a stable intraocular environment, though it does not directly manage the blood-retinal barrier in the way a VEGF Inhibitor would.

Dosage and Administration Protocols

The administration of Qlosi must be precise to ensure the desired miotic effect while avoiding systemic exposure. It is provided in single-use vials to remain PRESERVATIVE-FREE.

Administration Instructions:

• Wash hands thoroughly before use.
• Instill one drop in the affected eye(s). If using twice daily, the second dose may be administered 6 to 12 hours after the first.
• To minimize systemic absorption and potential side effects, use the technique for punctal occlusion: immediately after instilling the drop, press gently on the inner corner of the eye (near the nose) for at least one minute.
• If using other topical eye medications, wait at least 5 minutes between different drops.
• Contact lens wearers should remove their lenses before instillation and wait at least 10 minutes before reinserting them.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

The efficacy of Qlosi was established through the NEAR-1 and NEAR-2 Phase 3 clinical trials, conducted between 2020 and 2023. These studies focused on the drug’s ability to improve Distance-Corrected Near Visual Acuity (DCNVA) without compromising distance vision.

In these trials, a statistically significant proportion of participants treated with Qlosi 0.4% gained 3 lines or more (the equivalent of 15 letters) in near vision on a standard eye chart under low-light (mesopic) conditions at Day 14, Hour 1. Specifically, precise numerical data showed that visual improvement was rapid, often occurring within 15 to 30 minutes of administration.

Furthermore, research results indicated that the effect was durable, with many patients maintaining significant near-vision gains for up to 8 hours post-administration. Unlike higher concentrations of pilocarpine, the 0.4% formulation showed a mean change in distance visual acuity of less than one letter, confirming that the “pinhole effect” successfully isolated the near-vision benefit without creating a significant myopic shift or “blurring” of the horizon. These trials underscore Qlosi’s role as an efficacious TARGETED THERAPY for the aging eye.

Safety Profile and Side Effects

• Black Box Warning: There is currently NO Black Box Warning for Qlosi.

Common Side Effects (>10%):

• Headache (often referred to as “brow ache” due to ciliary muscle contraction).
• Eye redness (conjunctival hyperemia).
• Temporary blurred vision or “dimness” in low-light environments.

Serious Adverse Events:

• Retinal Detachment: Cholinergic agonists have been associated with rare instances of retinal detachment, as the contraction of the ciliary muscle can exert traction on the peripheral retina.
• Retinal Tears/Holes: Potential for secondary damage to the retinal periphery in susceptible individuals.
• Iritis/Uveitis: Potential for acute inflammation of the iris.

Management Strategies:

Patients should be screened with a dilated fundus exam prior to starting Qlosi to identify pre-existing retinal weaknesses. Monitoring for “floaters,” sudden flashes of light, or a “curtain” over the vision is mandatory. If these symptoms occur, the patient must seek immediate ophthalmic evaluation. Proper drop instillation and punctal occlusion are recommended to minimize systemic absorption, which helps prevent systemic cholinergic effects like bradycardia or hypotension.

Research Areas

Direct Clinical Connections: Current research (2024-2026) is investigating the impact of low-dose pilocarpine on goblet cell density and the ocular surface. Preliminary findings suggest that because Qlosi is PRESERVATIVE-FREE, it causes significantly less disruption to the tear film than older, preserved miotics, making it a viable option for patients with existing chronic ocular surface disease.

Generalization: The development of Biosimilars and Novel Delivery Systems is a broad area of active clinical trials. Researchers are exploring sustained-release intraocular implants and “smart” contact lenses that could deliver pilocarpine over a 24-hour period, eliminating the need for daily drops. There is also interest in the interaction between miotics and retinal pigment epithelium (RPE) health, particularly in older populations.

Severe Disease & Surgical Integration: While Qlosi is for presbyopia, research is looking at how pupil-modulating drops might serve as an adjunct to vitrectomies or certain cataract surgeries by stabilizing the pupil size post-operatively.

Disclaimer: These studies regarding sustained-release implants and surgical adjunct use are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Baseline Visual Acuity (Near and Distance), Tonometry (IOP measurement), and a Slit-lamp exam.
• Ocular Imaging: Fundus Photography or Optical Coherence Tomography (OCT) is recommended to ensure retinal stability.
• Screening: A thorough history of ocular surgeries, retinal detachment, or herpes simplex keratitis is required.

Monitoring and Precautions

• Vigilance: Patients should be warned about decreased night vision. Because the pupil is smaller, less light reaches the retina, which can make driving at night or in low-light conditions dangerous.
• Lifestyle: Advise the use of appropriate lighting for near tasks and remind patients that the effect is temporary.
• Do’s and Don’ts:
  • Do use the single-use vial immediately after opening and discard any remaining liquid.
  • Do report any sudden flashes of light or new floaters to your doctor immediately.
  • Don’t drive at night if you notice significant dimming of your vision.
  • Don’t use the medication if the vial is damaged or has been open for more than a few minutes.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Qlosi is a prescription medication that must be used under the supervision of a licensed eye care professional. All medical decisions regarding presbyopia treatment should be made in consultation with your doctor. The authors and publishers are not responsible for any adverse effects or consequences resulting from the use of the information contained herein.